文献速递眼底病与葡萄膜炎青光眼

无青光眼的前节新生血管化进展为新生血管性青光眼的预测因素及视力结局

Visual Outcomes in Eyes With Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2021-09-23

该回顾性队列研究分析了106眼无青光眼的前节新生血管化(ASNVWG)和245眼新生血管性青光眼(NVG),发现25%的ASNVWG眼进展为NVG,且与视网膜静脉阻塞(RVO)、较低基线视力及牵拉性视网膜脱离相关。早期PRP或玻璃体腔注射贝伐珠单抗(IVB)治疗与较好视力相关。

要点

  • ASNVWG眼25%进展为NVG,RVO、低基线视力、牵拉性视网膜脱离是危险因素。
  • 1周内≥1次PRP或IVB,或总共≥3次PRP或IVB,与6个月视力>20/200相关。

核心结论

  • ASNVWG眼进展为NVG与RVO、较低基线视力及牵拉性视网膜脱离相关。
  • NVG眼6个月视力≤20/200与RVO、就诊时玻璃体出血及未行PRP相关,早期PRP或IVB治疗有保护作用。

研究设计与样本

  • 回顾性临床队列研究,纳入106眼(94例)ASNVWG和245眼(225例)NVG。

主要发现

  • 25%的ASNVWG眼进展为NVG。

临床怎么用

  • 对ASNVWG患者应评估RVO、基线视力及牵拉性视网膜脱离以预测NVG风险。
  • 对NVG患者应积极处理玻璃体出血并尽早行PRP或IVB治疗以改善视力预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To find predictive factors of neovascular glaucoma (NVG) development in eyes with anterior segment neovascularization without glaucoma (ASNVWG), and poor visual outcomes in eyes that have already developed NVG. DESIGN: Retrospective, clinical cohort studies. METHODS: A retrospective chart review was performed on 106 eyes of 94 patients with ASNVWG and 245 eyes of 225 patients with NVG. Measured outcomes included the development of NVG at any time point of the disease for the ASNVWG arm, and a visual acuity of ≤20/200 at 6 months after initial presentation for the NVG arm. RESULTS: Overall, 25% of ASNVWG eyes progressed to NVG. Progression was associated with retinal vein occlusion (RVO) (P < .01), lower median presenting BCVA (P < .01), and concurrent traction retinal detachments (TRDs) (P = .025). Sixty-eight percent of NVG eyes had a BCVA of ≤20/200 by 6-month follow-up, which was associated with RVO (P = .005), vitreous hemorrhage on presentation (P = .001), and no panretinal photocoagulation (PRP) treatments (P < .001). BCVA >20/200 at 6 months was associated with ≥1 PRP or intravitreal bevacizumab (IVB) treatment within 1 week of presentation or ≥3 PRP or IVB treatments overall (P < .001). CONCLUSION: RVO, presenting visual acuity, and concurrent TRD are risk factors for NVG in eyes with ASNVWG. In eyes with NVG, RVO and concurrent vitreous hemorrhage are risk factors for ≤20/200 vision at 6 months, whereas treatment with ≥1 PRP or IVB within 1 week of presentation, or ≥3 treatments of PRP or IVB within 6 months are protective.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sastry A, Ryu C, Jiang X, et al. Visual Outcomes in Eyes With Neovascular Glaucoma and Anterior Segment Neovascularization Without Glaucoma. Am J Ophthalmol. 2021. PMID: 34562418. doi:10.1016/j.ajo.2021.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。